Levi & Korsinsky is investigating the Board of Directors of Human Genome Sciences, Inc. (“Human Genome” or the “Company”) (NasdaqGS: HGSI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to GlaxoSmithKline plc.
Click here to learn more about the investigation: http://zlk.9nl.com/human-genome, or call: 877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Human Genome shareholders will receive $14.25 per share of Human Genome stock they own. The transaction has a total approximate value of $3 billion. The investigation concerns whether the Human Genome Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether GlaxoSmithKline is underpaying for Human Genome shares, thus unlawfully harming Human Genome stockholders. In particular, at least one analyst set a price target for Human Genome stock at $23.00 per share.
If you own common stock in Human Genome and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/human-genome.Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.